Literature DB >> 26769433

Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review.

Annie Huang1, Isabel Castrejon2.   

Abstract

Patient-reported outcomes (PROs) are being increasingly recognized as important measures by rheumatologists. The objective of this review was to evaluate the frequency of use of PROs in studies of patients with polymyalgia rheumatica (PMR). A systematic literature search was performed in PubMed (up to April 2015) to identify any type of clinical studies reporting any type of PROs in patients with PMR. Articles were excluded if they did not include adults with PMR or did not report any PROs. Characteristics of each study such as study design, follow-up, treatment assessed if any, number of patients, mean age, gender, and a description of PROs used were collected to perform a descriptive analysis. From 118 initial studies captured, 28 articles met the predefined criteria, and 20 were finally included in this review. Ten studies (50 %) were randomized clinical trials (RCTs), and 8 (40 %) were cohorts. The most frequently reported domains were: pain (90 %), being the most frequent tool using a visual analogue scale; morning stiffness in minutes (85 %); and function (25 %), evaluated through the Health Assessment Questionnaire. Other domains such as patient global assessment, fatigue, quality of life, and anxiety and depression were infrequently reported. A larger proportion of PROs were included in cohorts in comparison with RCT. Pain and morning stiffness are the most frequently reported PROs. Other domains that may appear relevant for patients are infrequently reported, especially function.

Entities:  

Keywords:  Disease activity; Patient-reported outcomes; Polymyalgia rheumatica; Review

Mesh:

Year:  2016        PMID: 26769433     DOI: 10.1007/s00296-015-3416-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  41 in total

Review 1.  Measures of adult general functional status: SF-36 Physical Functioning Subscale (PF-10), Health Assessment Questionnaire (HAQ), Modified Health Assessment Questionnaire (MHAQ), Katz Index of Independence in activities of daily living, Functional Independence Measure (FIM), and Osteoarthritis-Function-Computer Adaptive Test (OA-Function-CAT).

Authors:  Daniel K White; Jessica C Wilson; Julie J Keysor
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

2.  The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.

Authors:  J F Fries; P W Spitz; D Y Young
Journal:  J Rheumatol       Date:  1982 Sep-Oct       Impact factor: 4.666

3.  Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis.

Authors:  A Proven; S E Gabriel; W M O'Fallon; G G Hunder
Journal:  J Rheumatol       Date:  1999-06       Impact factor: 4.666

4.  Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.

Authors:  Carlo Salvarani; Fabrizio Cantini; Laura Niccoli; Pierluigi Macchioni; Dario Consonni; Gianluigi Bajocchi; Marco Vinceti; Maria Grazia Catanoso; Lia Pulsatelli; Riccardo Meliconi; Luigi Boiardi
Journal:  Arthritis Rheum       Date:  2005-02-15

5.  Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens.

Authors:  O Di Munno; B Imbimbo; M Mazzantini; S Milani; G Occhipinti; G Pasero
Journal:  J Rheumatol       Date:  1995-08       Impact factor: 4.666

6.  Polymyalgia rheumatica: a 10-year epidemiologic and clinical study.

Authors:  T Y Chuang; G G Hunder; D M Ilstrup; L T Kurland
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

7.  Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica.

Authors:  Andrew Hutchings; Jane Hollywood; Donna L Lamping; Colin T Pease; Kuntal Chakravarty; Barbara Silverman; Ernest H S Choy; David G I Scott; Brian L Hazleman; Brian Bourke; Nagui Gendi; Bhaskar Dasgupta
Journal:  Arthritis Rheum       Date:  2007-06-15

8.  Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study.

Authors:  Maria Grazia Catanoso; Pierluigi Macchioni; Luigi Boiardi; Nicolò Pipitone; Carlo Salvarani
Journal:  Arthritis Rheum       Date:  2007-12-15

Review 9.  Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR.

Authors:  Sarah L Mackie; Seher Arat; Jose da Silva; Catia Duarte; Sue Halliday; Rod Hughes; Marianne Morris; Colin T Pease; Jeffrey W Sherman; Lee S Simon; Maggie Walsh; René Westhovens; Samy Zakout; John R Kirwan
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

10.  "An impediment to living life": why and how should we measure stiffness in polymyalgia rheumatica?

Authors:  Sarah Louise Mackie; Rodney Hughes; Margaret Walsh; John Day; Marion Newton; Colin Pease; John Kirwan; Marianne Morris
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

View more
  1 in total

1.  Depression and depressive symptoms in patients with polymyalgia rheumatica: discussion points, grey areas and unmet needs emerging from a systematic review of published literature.

Authors:  Ciro Manzo; Ayar Nizama-Via; Marcin Milchert; Marco Isetta; Alberto Castagna; Maria Natale; Jordi Serra-Mestres
Journal:  Reumatologia       Date:  2020-12-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.